TABLE 1.

Baseline characteristics of the study population.

	Placebo (N = 6)	Selnoflast, 450 mg (N = 13)
Age (years)
Mean (SD)	29.4 (6.3)	38.8 (13.7)
Median (Min—Max)	27.2 (23.8–40.8)	35.7 (19.9–64.6)
Sex (n [%])
Male	5 (83.3%)	5 (38.5%)
Female	1 (16.7%)	8 (61.5%)
Race (n [%])
White	6 (100%)	13 (100%)
Weight (kg)
Mean (SD)	86.0 (9.6)	71.4 (13.7)
Median (Min—Max)	85.3 (70.0–97.1)	71.5 (49.9–93.8)
Partial Mayo Clinic Score
Mean (SD)	5.5 (1.5)	5.9 (1.0)
Median (Min—Max)	5.5 (4.0–8.0)	6 (4.0–8.0)
Stool calprotectin (μg/g)
Mean (SD)	5673.2 (11 911.6)	1581.0 (1932.0)
Median (Min—Max)	667.6 (99.0–29947.0)	694.5 (59.0–6284.8)
Prior anti‐TNF therapy (n [%])
Infliximab or biosimilar	0	1 (7.7%)
Golimumab	0	1 (7.7%)
Prior immunosuppressive therapy (n [%])
Vedolizumab	0	2 (15.4%)
Risankizumab	1 (16.7%)	0
Azathioprine	2 (33.3%)	1 (7.7%)